PARIS (Reuters) – The chief executive of Eli Lilly and Co’s Alzheimer’s imaging unit is confident it can create a training program for its imaging drug that will satisfy concerns raised by U.S. regulators.
Continue reading here:
Avid CEO confident in ... continue reading
U.S. health reviewers’ main concern with Eli Lilly & Co’s imaging agent for Alzheimer’s tests is whether technicians can properly read the scans and how useful they are in assessing the degenerative disease.
Read more:
FDA staff questions Lilly drug ... continue reading
Vernon Hills, Ill. — Illinois-based biotechnology developer Applied NeuroSolutions and Indianapolis-based drug maker Eli Lilly and Co. announced Tuesday they’ll continue to collaborate on the development of products for the early diagnosis and treatment of Alzheimer’s disease. Applied NeuroSolutions will receive $750,000 from Lilly and later may get up to ... continue reading